12:29 PM EDT, 04/26/2024 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen-Cilag International said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Rybrevant (amivantamab), in combination with chemotherapy for the treatment of adult patients with advanced non-small cell lung cancer.

The recommendation is supported by the phase 3 Papillon study that met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival in lung cancer patients, the drugmaker said.

Price: 146.49, Change: -0.33, Percent Change: -0.22